马拉维9月龄至12岁儿童伤寒结合疫苗的安全性与免疫原性:一项双盲随机对照试验的巢式亚组研究
在马拉维开展的一项3期双盲随机对照试验的巢式亚组研究,将631名9月龄至12岁儿童按1:1随机分配接受伤寒结合疫苗(TCV)或对照疫苗(MCV-A)。TCV组抗Vi IgG在28天较基线升高超过500倍,至730-1035天仍较基线高11倍以上,两组局部和全身反应原性相似。
要点
- TCV组抗Vi IgG从基线4.2 EU/mL升至28天2383.7 EU/mL,730-1035天降至48.0 EU/mL,仍为基线的11倍以上。
- MCV-A组抗Vi IgG在基线、28天和730-1035天分别为4.3、4.4和4.6 EU/mL,基本不变。
- TCV组与MCV-A组局部反应原性分别为8/304(3%)和3/293(1%),全身反应原性均为27/304(9%)和27/293(9%)。
核心结论
- 本研究提供了TCV在马拉维9月龄至12岁儿童中长达730-1035天的安全性、耐受性和免疫原性证据。
研究设计与样本
- 本亚组研究巢式于一项在马拉维布兰太尔Ndirande镇Ndirande健康中心开展的3期双盲平行设计随机对照试验。
- 631名9月龄至12岁、无已知免疫抑制或慢性健康问题(包括HIV或严重营养不良)的儿童按1:1随机接受TCV或对照疫苗(MCV-A)肌肉注射。
- 免疫原性通过ELISA检测基线和接种后28天及730-1035天的抗Vi抗体;因COVID-19,第730天访视延长至1035天。
主要发现
- TCV组抗Vi IgG几何平均滴度从基线4.2 EU/mL(95%CI 4.0-4.4)升至28天2383.7 EU/mL(2087.2-2722.3),730-1035天降至48.0 EU/mL(39.9-57.8),仍较基线高11倍以上。
- MCV-A组抗Vi IgG滴度基本不变:基线4.3 EU/mL(4.0-4.5),28天4.4 EU/mL(4.0-4.7),730-1035天4.6 EU/mL(4.2-5.0)。
- TCV组与MCV-A组局部反应原性分别为8/304(3%,95%CI 1.3-5.1)和3/293(1%,0.4-3.0)。
- TCV组与MCV-A组全身反应原性分别为27/304(9%,6.2-12.6)和27/293(9%,6.4-13.1)。
- 相关非征集性不良事件在TCV组和MCV-A组分别为8/304(3%,1.3-5.1)和8/293(3%,1.4-5.3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Typhoid fever is a substantial public health problem in Africa, yet there are few clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of Typbar TCV in Malawi. METHODS: This substudy was nested within a phase 3, double-blind, parallel design, randomised controlled trial of TCV in children from Ndirande Health Centre in Ndirande township, Blantyre, Malawi. To be eligible, participants had to be aged between 9 months and 12 years with no known immunosuppression or chronic health conditions, including HIV or severe malnutrition; eligible participants were enrolled into three strata of approximately 200 children (9-11 months, 1-5 years, and 6-12 years), randomly assigned (1:1) to receive TCV or control (meningococcal serogroup A conjugate vaccine [MCV-A]) intramuscularly. Serum was collected before vaccination and at 28 days and 730-1035 days after vaccination to measure anti-Vi antibodies by ELISA. Because of COVID-19, day 730 visits were extended up to 1035 days. This nested substudy evaluated reactogenicity, safety, and immunogenicity by age stratum. Safety outcomes, analysed in the intention-to-treat population, included solicited adverse events within 7 days of vaccination (assessed on 3 separate days) and unsolicited adverse events within 28 days of vaccination. This trial is registered with ClinicalTrials.gov, NCT03299426. FINDINGS: Between Feb 22 and Sept 6, 2018, 664 participants were screened, and 631 participants were enrolled and randomly assigned (320 to the TCV group and 311 to the MCV-A group). 305 participants in the TCV group and 297 participants in the MCV-A group were vaccinated. Among TCV recipients, anti-Vi IgG geometric mean titres increased more than 500 times from 4·2 ELISA units (EU)/mL (95% CI 4·0-4·4) at baseline to 2383·7 EU/mL (2087·2-2722·3) at day 28, then decreased to 48·0 EU/mL (39·9-57·8) at day 730-1035, remaining more than 11 times higher than baseline. Among MCV-A recipients, anti-Vi IgG titres remained unchanged: 4·3 EU/mL (4·0-4·5) at baseline, 4·4 EU/mL (4·0-4·7) on day 28, and 4·6 EU/mL (4·2-5·0) on day 730-1035. TCV and MCV-A recipients had similar solicited local (eight [3%] of 304, 95% CI 1·3-5·1 and three [1%] of 293, 0·4-3·0) and systemic (27 [9%] of 304, 6·2-12·6 and 27 [9%] of 293, 6·4-13·1) reactogenicity. Related unsolicited adverse events occurred similarly in TCV and MCV-A recipients in eight (3%) of 304 (1·3-5·1) and eight (3%) of 293 (1·4-5·3). INTERPRETATION: This study provides evidence of TCV safety, tolerability, and immunogenicity up to 730-1035 days in Malawian children aged 9 months to 12 years. FUNDING: Bill & Melinda Gates Foundation.
引用
- Nampota-Nkomba N, Nyirenda OM, Khonde L, et al. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. Lancet Glob Health. 2022. PMID: 35961356. doi:10.1016/S2214-109X(22)00275-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。